Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.14.14.3 (
luciferase
)
38,195
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A better understanding of breast cancer pathogenesis would contribute to improved diagnosis and therapy and potentially decreased mortality rates. Here, we found that the
MORC family CW-type zinc finger 4
(
MORC4
) overexpression in breast cancer tissues is associated with poor survival, and the short-interfering RNA knockdown of
MORC4
suppresses the growth of breast cancer cells by promoting apoptosis. To investigate the mechanisms associated with
MORC4
upregulation, microRNAs potentially targeting
MORC4
were analyzed, with miR-193b-3p identified as the regulator and a negative correlation between miR-193b-3p and
MORC4
expression determined in both breast cancer cell lines and tissues. Further analysis verified that
MORC4
silencing did not affect miR-193b-3p expression, although altered miR-193b-3p expression attenuated
MORC4
protein levels. Moreover, dual-
luciferase
reporter assays verified miR-193b-3p binding to the 3' untranslated region of
MORC4
. Furthermore, restoration of miR-193b-3p expression in breast cancer cells led to decreased growth and activation of apoptosis, which was consistent with results associated with
MORC4
silencing in breast cancer cells. These results identified
MORC4
as differentially expressed in breast cancer cells and tissues and its downregulation by miR-193b-3p, as well as its roles in regulating the growth of breast cancer cells via regulation of apoptosis. Our findings offer novel insights into potential mechanisms associated with breast cancer pathogenesis.
...
PMID:MORC4 is a novel breast cancer oncogene regulated by miR-193b-3p. 3032 Sep 20